About This Tool

The Kevzara (sarilumab) Dosing Calculator is a clinical support tool designed for healthcare professionals. It helps determine the appropriate initial dose and subsequent dose modifications of Kevzara for patients with Rheumatoid Arthritis (RA), Polymyalgia Rheumatica (PMR), and Systemic Juvenile Idiopathic Arthritis (sJIA). This calculator simplifies complex dosing protocols based on patient-specific parameters, including indication, body weight, and key laboratory values.

Outputs Explained

After processing the inputs, the calculator provides a clear, actionable recommendation. The output includes:

• Dosing Recommendation: States whether to initiate, continue, reduce, interrupt, or permanently discontinue therapy.
• Specific Dose and Frequency: For treatment initiation or modification, it specifies the exact dosage (e.g., 200 mg) and administration schedule (e.g., every 2 weeks).
• Clinical Rationale: A brief explanation details why the recommendation was made, referencing the specific lab values or patient parameters that triggered the decision (e.g., "Based on ANC of 800 cells/mm³").
• Resumption Criteria: For treatment interruptions, it outlines the conditions under which therapy can be safely resumed.

How to Use the Calculator

To use the calculator, follow these steps:

1. Select Indication: Choose the appropriate condition (RA, PMR, or sJIA) from the dropdown menu. If sJIA is selected, a weight input field will appear.
2. Enter Patient Weight (for sJIA): Input the patient's weight and select the unit (kg or lbs). Weight is required for determining the correct dosing frequency in sJIA.
3. Enter Current Dose & Labs (Optional): For patients already on therapy, input their current Kevzara dose and recent lab results (ANC, Platelets, ALT/AST) to check for necessary dose modifications. You must also provide the lab's Upper Limit of Normal (ULN) to assess liver function tests.
4. Calculate: Click the "Calculate Dose" button to generate the recommendation.

Dosing Overview

Kevzara dosing is indication-specific. The standard recommended doses are as follows:

Dose modifications may be required based on lab abnormalities, such as neutropenia, thrombocytopenia, or elevated liver enzymes.

Switching to Kevzara

When switching a patient to Kevzara from another biologic or targeted synthetic DMARD, healthcare providers should consider the half-life and mechanism of action of the previous medication to avoid overlapping immunosuppressive effects. Consult the full prescribing information for detailed guidance on transitioning patients to Kevzara therapy.

Missed Dose

If a patient misses a dose of Kevzara, they should be instructed to administer the dose as soon as they remember. Thereafter, they should resume their regular dosing schedule from the date of the last administered dose. Do not double the dose to make up for a missed one.

Safety Alerts

Kevzara carries important safety warnings. Do not initiate treatment in patients with an active infection, low neutrophil or platelet counts, or elevated liver enzymes. Key safety considerations include:

• Serious Infections: Increased risk of serious bacterial, fungal, viral, and opportunistic infections.
• Hematologic Abnormalities: Can cause neutropenia (ANC < 2,000) and thrombocytopenia (Platelets < 150,000).
• Hepatotoxicity: Risk of elevated liver enzymes (ALT/AST > 1.5x ULN).
• GI Perforation: Use with caution in patients with a history of diverticulitis.

Regular monitoring of complete blood counts (CBC) and liver function tests (LFTs) is required before and during therapy.

Frequently Asked Questions

• Why is patient weight needed for sJIA but not RA or PMR?
  For sJIA, the dosing frequency is weight-dependent to ensure appropriate drug exposure in a pediatric population with varying body sizes. The schedule is every 3 weeks for patients under 50 kg and every 2 weeks for those 50 kg or greater.
• What does the calculator recommend if ANC is below 500 cells/mm³?
  An ANC below 500 cells/mm³ is a critical value. The calculator will recommend Discontinue Permanently, in line with official prescribing guidelines.
• Do I need to enter lab values for a new patient?
  No. If you leave the lab fields blank, the calculator provides the standard initiation dose for the selected indication. However, baseline labs (CBC, LFTs) should always be checked prior to starting therapy as per the prescribing information.
• What is 'ULN' and why is it required?
  ULN stands for Upper Limit of Normal, which is the highest value in the normal range for a lab test (like ALT or AST). Since ULN can vary between laboratories, you must enter your lab's specific value for the calculator to accurately assess the severity of liver enzyme elevation.
• Can this tool be used for patients with renal or hepatic impairment?
  The tool does not specifically account for renal or severe hepatic impairment. Dosing in these populations requires careful clinical judgment and reference to the full prescribing information. No dose adjustment is needed for mild to moderate renal or mild hepatic impairment.
• What are the available formulations of Kevzara?
  Kevzara is available as a single-dose pre-filled syringe or a single-dose pre-filled pen, both containing either 150 mg or 200 mg of sarilumab.
• What happens if a patient's platelets are between 50,000 and 100,000/mm³?
  The calculator will recommend Interrupt Treatment. Therapy may be resumed at a reduced dose of 150 mg once the platelet count recovers to over 100,000/mm³.
• Is this calculator a substitute for clinical judgment?
  No. This tool is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult the full Prescribing Information before making any clinical decisions.

References

• KEVZARA (sarilumab) Full Prescribing Information – U.S. Food and Drug Administration (FDA)
• Kevzara HCP Official Website – Sanofi and Regeneron Pharmaceuticals
• 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis – American College of Rheumatology
• 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis – American College of Rheumatology